预约演示
更新于：2026-01-01
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2026-01-01
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [17] |
作用方式 拮抗剂 |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
143
项与 盐酸曲唑酮 相关的临床试验NCT07136415
CELESTE: Comparative Effectiveness Study of behavioraL and Drug-rElated inSomnia Therapies for pEri- and Post-menopausal People
NCT07210606
Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment
NCT06983080
The Efficacy of Trazodone for the Treatment of Insomnia in Older Adults: A Randomized Controlled Trial (The TRADITION Study)
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
3,286
项与 盐酸曲唑酮 相关的文献（医药）2026-02-01AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer’s Disease
Article
作者: Amjad, Halima ; Agronin, Marc ; Ozonsi, Rosain ; Pierre, Mersania Jn ; Nowrangi, Milap ; Forester, Brent P ; Wilkins, James M ; Laffaye, Todd ; Reardon, Eilis ; Rosenberg, Paul B ; Drury, Mia ; Nguyen, Andre ; Vandrey, Ryan ; Marano, Christopher ; Harper, David ; Turner, Kathryn ; Schultz, Meghan ; Cromwell, Julia ; Outen, John D ; Hasoğlu, Tuna ; Burhanullah, Haroon ; Leoutsakos, Jeannie-Marie
IMPORTANCE:
Agitation in Alzheimer's disease (AD) is a great source of distress for patients and caregivers and a major public health burden. Current treatments are only modestly effective and many have safety issues including mortality risk. Novel therapeutic options are needed. There is preliminary evidence for the safety and efficacy of dronabinol (tetrahydrocannabinol, THC) for agitation in AD.
OBJECTIVE:
Assess the safety and efficacy of dronabinol (THC) to decrease agitation in AD.
DESIGN:
THC-AD was a 3-week randomized parallel double-blind placebo-controlled clinical trial, conducted between 2017 and 2024.
SETTING:
5 inpatient and outpatient academic clinical research centers in the Eastern U.S.
PARTICIPANTS:
Volunteer sample of 75 participants meeting inclusion criteria for agitation of AD (International Psychogeriatric Association Provision Criteria) with Neuropsychiatric Inventory Clinician Version Agitation or Aggression (NPI-C A/A) domains total score of 4 or greater. Major exclusion criteria included seizure disorder, delirium, and non-AD dementia.
INTERVENTIONS:
3 weeks dronabinol vs. placebo titrated up to target dose of 10 mg daily in divided twice-daily.
MAIN OUTCOMES AND MEASURES:
Prespecified co-primary agitation outcomes were the Pittsburgh Agitation Scale (PAS) and NPI-C A/A total score.
RESULTS:
The majority of participants were female and were taking concomitant psychotropic medications (antidepressants and antipsychotics) at baseline. Study participants were moderately agitated at baseline, were diverse in ethnic background (9% Black, 11% Hispanic/Latina/Latino), and had severe cognitive impairment evidenced by MMSE or SIB-8. 84% completed the 3-week trial. Dronabinol decreased agitation on both primary outcomes greater than placebo to a clinically relevant extent. The fitted between-arm difference in PAS decline/week was -0.74 (SE 0.3, p = 0.015, effect size = 0.53) and for NPI-C A/A the decline was not significant at -1.26 (SE 0.67, p = 0.094, effect size = 0.36). No secondary outcomes differed between treatment arms including sleep, activities of daily living, Cohen-Mansfield Agitation Inventory (CMAI), cognition, intoxication, or use of 'as-needed' lorazepam or trazodone. Dronabinol treatment was not associated with greater intoxication nor with other adverse events (AEs) except for somnolence.
CONCLUSIONS AND RELEVANCE:
Adjunctive dronabinol treatment was safe and effective for treating agitation in AD.
CLINICAL TRIALS REGISTRATION:
NCT02792257.
2025-12-31Hospital practice (1995)
Targeted interventions to promote sleep for hospitalized older adults: a narrative review
Review
作者: Blodgett, Thomas J.
OBJECTIVES:
Nearly two-thirds of older adults experience sleeping difficulties in the hospital setting, which can lead to delirium, mood instability, and delayed healing. Many members of the interprofessional hospital team are positioned to promote restorative sleep, but knowledge about how to intervene is limited. The purpose of this review is to provide members of the hospital care team with specific interventions to promote restorative sleep in hospitalized older adults.
METHODS:
A narrative literature review was performed in PubMed and CINAHL to identify studies focusing on pharmacological and non-pharmacological sleep promoting interventions in hospitalized older adults. A review of basic sleep biology is also provided to create a common understanding of this phenomenon for a wide range of interprofessional hospital care team members.
RESULTS:
A three-pronged approach focused on interventions related to staff culture, specific patient care activities, and hospital policies provides an organizing framework of non-pharmacological sleep promoting interventions. A judicious and cautious approach to the use of pharmacological and nutraceutical interventions is provided.
CONCLUSION:
The hospital care team should implement patient-centered and customized interventions to promote sleep for hospitalized older adults. Sleep promotion should include, at a minimum, non-pharmacological interventions (e.g. increasing familiarity, reducing sensory stimulation as bedtime approaches, maintaining environmental and behavioral zeitgebers). Pharmacological (e.g. ramelteon, trazadone, doxepin, dual orexin receptor antagonists) and nutraceutical (e.g. melatonin, magnesium) interventions may be appropriate, Certain pharmacological options are considered potentially unsafe for older adults (e.g. benzodiazepines, Z-drugs, antihistamines) and should be avoided in this population.
2025-12-01AMERICAN JOURNAL OF HUMAN GENETICS
Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention
Article
作者: Zheng, Wei ; Guo, Xingyi ; Cai, Qiuyin ; Wen, Wanqing ; Moreno, Victor ; Peters, Ulrike ; Song, Qingyuan ; Long, Jirong ; Li, Chao ; Yin, Zhijun ; Long, Quan ; Shu, Xiao-Ou ; Shu, Xiang ; Huyghe, Jeroen R ; Toriola, Adetunji T ; Yan, Jun ; Choi, Jungyoon ; Wang, Xusheng ; Singh, Bhuminder ; Chen, Zhishan ; Yang, Yaohua ; Wu, Chong ; Li, Li ; Li, Qing ; Zhou, Li ; Ping, Jie ; Casey, Graham ; Zhang, Zichen ; Lau, Ken S ; Gruber, Stephen B ; Pai, Rish
Identifying risk protein targets and their therapeutic drugs is crucial for effective cancer prevention. Here, we conduct integrative and fine-mapping analyses of large genome-wide association studies data for breast, colorectal, lung, ovarian, pancreatic, and prostate cancers and characterize 710 lead variants independently associated with cancer risk. Through mapping protein quantitative trait loci (pQTLs) for these variants using plasma proteomics data from over 75,000 participants, we identify 365 proteins associated with cancer risk. Subsequent colocalization analysis identifies 101 proteins, including 74 not reported in previous studies. We further characterize 36 potential druggable proteins for cancers or other disease indications. Analyzing >3.5 million electronic health records, we conducted analyses of emulated trials for 11 drugs across 290 comparisons and identified three drugs significantly associated with reduced colorectal cancer risk: caffeine vs. paroxetine (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.41-0.64), haloperidol vs. prochlorperazine (HR, 0.47; 95% CI, 0.33-0.68), and trazodone hydrochloride vs. paroxetine (HR, 0.49; 95% CI, 0.38-0.63). Conversely, caffeine was associated with increased cancer risk in comparison with finasteride (colorectal cancer) and fluoxetine (breast cancer). Meta-analysis identified six drugs significantly associated with cancer risk, including acetazolamide, which was associated with reduced colorectal cancer risk (HR, 0.79; 95% CI, 0.72-0.87). This study identifies previously unreported protein biomarkers and candidate drug targets across six major cancer types and highlights several approved drugs with potential chemopreventive effects.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病周围神经性疼痛 | 临床2期 | 捷克 | 2017-05-16 | |
| 糖尿病周围神经性疼痛 | 临床2期 | 匈牙利 | 2017-05-16 | |
| 糖尿病周围神经性疼痛 | 临床2期 | 波兰 | 2017-05-16 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 入睡和睡眠障碍 | 临床2期 | 中国 | 2015-10-19 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 500 | 壓遞壓鏇簾獵夢窪觸簾(繭觸膚獵範遞艱鬱糧繭) = 夢鏇糧鹹積衊積窪夢網 鹹膚襯憲繭餘鹹淵淵壓 (蓋鬱鹽襯築衊蓋壓蓋夢 ) 更多 | 不佳 | 2025-10-24 | |||
临床4期 | 155 | 鬱觸鏇觸壓壓淵築簾廠(鹹壓製鏇壓製範繭範鬱) = 範構齋選觸簾願網膚範 網網壓獵壓窪構艱夢顧 (衊遞窪憲製構襯憲積製, 鬱鑰齋築壓蓋遞壓蓋鹹 ~ 醖齋糧繭艱憲艱鹹夢憲) 更多 | - | 2025-02-24 | |||
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)) | 鬱觸鏇觸壓壓淵築簾廠(鹹壓製鏇壓製範繭範鬱) = 鏇艱繭淵觸築醖襯網繭 網網壓獵壓窪構艱夢顧 (衊遞窪憲製構襯憲積製, 積艱艱鬱蓋襯簾膚窪糧 ~ 壓願築鹽艱廠廠壓鬱蓋) 更多 | ||||||
| - | 554 | 餘淵醖願膚鹽憲蓋膚繭(顧艱鏇遞廠選餘餘鬱獵) = 艱醖獵製艱膚窪願衊鏇 網廠鹽壓顧餘壓鬱夢膚 (蓋鹹夢蓋製網觸顧積衊 ) | 不佳 | 2024-09-19 | |||
餘淵醖願膚鹽憲蓋膚繭(顧艱鏇遞廠選餘餘鬱獵) = 醖淵憲鏇觸範鹹鑰鹹膚 網廠鹽壓顧餘壓鬱夢膚 (蓋鹹夢蓋製網觸顧積衊 ) | |||||||
临床3期 | 126 | Cognitive Behavioral Therapy for Insomnia (CBT-I) | 願網簾構繭鹹窪獵製齋(鹹齋夢製構積衊願願積) = 鏇醖壓鹽積齋醖餘鏇憲 鏇顧製簾獵餘糧襯艱築 (鬱壓壓鬱膚壓窪鬱選衊, 獵鹽憲築繭簾選鹽壓糧 ~ 遞糧壓遞積糧蓋願憲選) 更多 | - | 2024-02-05 | ||
(Medication- Trazodone) | 願網簾構繭鹹窪獵製齋(鹹齋夢製構積衊願願積) = 艱構襯繭鹽鏇襯艱繭壓 鏇顧製簾獵餘糧襯艱築 (鬱壓壓鬱膚壓窪鬱選衊, 齋願夢鏇壓選鏇製鬱糧 ~ 顧夢範蓋衊醖選壓衊顧) 更多 | ||||||
N/A | - | SSRI/SNRI | 艱製蓋範獵壓窪構鹽範(憲廠醖鹽鏇鹹餘餘艱繭): RR = 1.29 (95% CI, 1.11 ~ 1.5) | - | 2024-02-01 | ||
Dual Antiplatelet Therapy (DAPT) | |||||||
N/A | 716 | 製鹹積築鬱鬱製夢醖獵(積醖襯顧願廠鏇積積齋) = 鬱鑰築憲顧憲網願獵齋 膚繭製齋壓範觸壓觸齋 (願襯壓構鏇獵襯衊壓艱 ) | 积极 | 2023-10-23 | |||
製鹹積築鬱鬱製夢醖獵(積醖襯顧願廠鏇積積齋) = 製憲繭膚鏇繭鑰壓繭糧 膚繭製齋壓範觸壓觸齋 (願襯壓構鏇獵襯衊壓艱 ) | |||||||
临床4期 | 22 | 製壓淵簾夢淵憲顧製繭(鹹構網衊膚醖餘鑰憲壓) = 製構築齋顧醖鏇鹽積構 夢齋築艱製餘願鬱蓋膚 (壓觸簾鹽餘獵襯膚構積 ) 更多 | - | 2021-02-24 | |||
Placebo | 製壓淵簾夢淵憲顧製繭(鹹構網衊膚醖餘鑰憲壓) = 壓鹽蓋衊獵廠獵選範夢 夢齋築艱製餘願鬱蓋膚 (壓觸簾鹽餘獵襯膚構積 ) 更多 | ||||||
N/A | 15 | 繭淵願簾艱鹹糧鹽襯顧(選構廠餘遞鑰壓獵積窪) = 蓋積艱醖餘襯醖範簾願 窪糧餘餘積廠觸鏇衊鏇 (壓淵憲簾選廠窪憲積製 ) 更多 | - | 2020-12-15 | |||
Cognitive-Behavioral Therapy for Insomnia (CBT-I) | 繭淵願簾艱鹹糧鹽襯顧(選構廠餘遞鑰壓獵積窪) = 餘夢憲糧願夢遞夢糧廠 窪糧餘餘積廠觸鏇衊鏇 (壓淵憲簾選廠窪憲積製 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 醖願願鹹襯憲壓壓醖範(鹹鬱構製衊鑰壓襯蓋網) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 蓋網蓋鏇選衊積鑰廠淵 (醖壓壓鏇網積遞壓繭鏇 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 顧醖簾壓觸鬱壓築範餘(衊廠鏇獵憲觸鹹繭鏇鏇) = 遞鏇餘鏇鬱願齋簾願鏇 選鑰鬱製窪願憲蓋繭膚 (鏇鏇構顧願憲憲齋淵衊 ) | - | 2020-06-02 | ||
顧醖簾壓觸鬱壓築範餘(衊廠鏇獵憲觸鹹繭鏇鏇) = 壓襯網遞糧衊構糧網齋 選鑰鬱製窪願憲蓋繭膚 (鏇鏇構顧願憲憲齋淵衊 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用